6-Chloro-4-methylpyridazin-3-amine

I. Product Basic Information Overview

II. Properties

3-Amino-4-methyl-6-chloropyridazine is a halogenated pyridazine heterocyclic compound. Its core skeleton is a pyridazine ring, with an amino group at position 3, a methyl group at position 4, and a chlorine atom at position 6. It appears as off-white to light brown crystalline powder, with a melting point of approximately 137 °C, a predicted boiling point of approximately 360 °C, and a density of approximately 1.349 g/cm³. The compound is weakly basic (predicted pKa approximately 4.49) and can form salts with acids. It has low solubility in water but is soluble in organic solvents such as alcohols and ethers.

The chlorine atom and amino group in the molecule are two key functional handles: the chlorine atom can participate in nucleophilic substitution, cross-coupling, and other reactions; the amino group can undergo acylation, alkylation, or diazotization transformations. This structural feature makes it a high-value building block and intermediate in heterocyclic medicinal chemistry.

III. Applications

Key intermediate for Risdiplam. This is the most core high-end application direction of this product. Risdiplam is an oral drug used for the treatment of spinal muscular atrophy (SMA), and 3-amino-4-methyl-6-chloropyridazine is a key pyridazine fragment in its synthetic route. SMA belongs to the rare disease field, with extremely high requirements for intermediate purity, impurity profile control, and batch consistency. The supplier’s process maturity and quality system directly determine the registration and production progress of the downstream API.

General reagent for organic synthesis. As an amino-chloropyridazine building block, it is widely used to construct more complex heterocyclic molecule libraries and to serve structure-activity relationship studies and process route exploration during the drug discovery stage.

Agrochemical intermediate direction. Pyridazine structures are also used in the pesticide field, and this compound can serve as a synthetic intermediate for active molecules such as insecticides and herbicides.

Antitumor and heterocyclic drug R&D. Our company positions it as part of its product line of antitumor, antiviral, and other heterocyclic drug intermediates, supporting innovative pharmaceutical companies’ route scale-up needs from gram scale to ton scale.

IV. Safety Information

This product is classified under GHS as Warning. It is not a highly toxic or extremely toxic substance, but it has clear irritant and harmful-if-swallowed risks.

Storage requirements: Protect with inert gas, store at 2–8 °C, protected from light, sealed. It is sensitive to air and light. After opening, it should be used as soon as possible or resealed after re-purge with inert gas.

Engineering control recommendations: Weighing and charging are recommended in areas equipped with local exhaust ventilation; operators should complete GHS hazard communication training; in case of leakage, appropriate personal protective equipment should be used to collect the material into a closed container and avoid dust generation.

V. Why Choose Us: Production Advantages and Capacity of Shanghai Lizhuo (SHLZ Pharma)

When customers screen suppliers of 3-amino-4-methyl-6-chloropyridazine, what they really care about is not “whether the product is available,” but whether the process is stable, whether batches are consistent, whether scale-up is reliable, whether supply is continuous, and whether problems can be responded to quickly. This is precisely the core competitiveness that distinguishes Shanghai Lizhuo (Shanghai Lizhuo Pharmaceutical Technology Co., Ltd.) from traders and scattered small manufacturers.

1. Ton-scale routine supply capability, seamless connection from samples to mass production

3-Amino-4-methyl-6-chloropyridazine is a regularly produced product of our company, rather than a temporary outsourced or project-based product. We can formally supply batch requirements from small-scale trial samples to more than tonnage. Our supply capability covers the complete chain from process R&D and pilot validation to commercial scale-up. This means customers do not need to change suppliers at different stages, and the process route and impurity profile remain continuous during scale-up, significantly reducing the risks of downstream API registration and process changes.

2. In-house R&D and pilot platform—not “pure trading,” nor “laboratory-only”

Shanghai Lizhuo is a subsidiary of Shenzhen Rich Chemical and is positioned as a comprehensive technology enterprise integrating R&D, production, and sales. The company has:

A 1,000 m21,000 m2 R&D laboratory, capable of undertaking gram-scale to kilogram-scale custom synthesis and route optimization;

Two pilot production workshops in Wuhan, equipped with 20 reactors of 50 L–1,000 L, with scale-up production capacity from hundreds of kilograms to ton scale;

Ultra-low-temperature reaction capability (−120 °C), high-temperature circulation equipment (−40 °C to 200 °C), vacuum/atmospheric distillation columns (2–6 m), molecular distillation and solid-liquid distillation, and other supporting equipment, covering various process types such as ultra-low temperature, continuous operation, nitration, nitro reduction, and epoxidation.

For pyridazine-type heterocyclic intermediates, low-temperature rate control, selective chlorination/amination, and distillation purification are often key difficulties in process scale-up. The above hardware and engineering experience mean that we are not “simply scaling up a laboratory route,” but a partner with practical engineering scale-up capabilities.

3. Technical team and collaboration network: PhD/Master’s-led, deep industry-academia-research collaboration

Lizhuo’s R&D personnel are all PhD and Master’s technical backbones who have long been engaged in pharmaceutical synthesis and have both laboratory research capabilities and engineering scale-up experience. At the same time, the company maintains project cooperation with institutions such as the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, and the College of Pharmaceutical Sciences, Zhejiang University, and has external intellectual support in new drug intermediate route design, impurity analysis, and process optimization. For customers, this means that when projects encounter abnormal impurity profiles, polymorph issues, yield bottlenecks, or changes in regulatory starting materials, we have a technical team that can substantively intervene and solve problems, rather than merely a “quote-and-ship” channel.

4. Focus on heterocyclic/antitumor/antiviral intermediates; category focus brings process depth

Lizhuo’s main directions are intermediates for antitumor, psycho-neurological, antiviral, hypoglycemic, and antibacterial drugs, and it continues to lay out in the field of innovative drug intermediates. As a key building block of Risdiplam (an SMA therapeutic drug), 3-amino-4-methyl-6-chloropyridazine is highly consistent with the company’s core track of heterocyclic drug intermediates. Focus brings not category stacking, but process reuse of similar reactions, transfer of impurity control experience, and deep understanding of the downstream quality requirements of this product. We know better than general suppliers that “sell everything” what will be scrutinized in customer audits and associated reviews for this type of halogenated aminopyridazine.

5. Quality and compliance orientation: supporting the full lifecycle from R&D to commercialization

Lizhuo is committed to providing global pharmaceutical companies and new drug R&D institutions with intermediates and API solutions covering the full lifecycle from early product development to drug marketing. We understand that for an intermediate used in SMA drugs or innovative drug projects, what suppliers need is not only “assay compliance,” but also batch-to-batch consistency, traceability of impurity profiles, controllability of process changes, and the ability to respond to customer audits and regulatory inquiries. With the values of “seeking development through quality and honoring commitments,” we embed the quality system into every link from route development to commercial supply. For customers advancing China, U.S., or EU registration or associated review, choosing a manufacturer that itself has process understanding and is willing to cooperate on quality agreements and audits is far safer and more economical than piecing together low-price sources from multiple traders.

6. Response speed and service positioning: short decision chain, direct technical interface

As an integrated R&D-production-sales enterprise headquartered in Shanghai with R&D and pilot bases in Wuhan, Lizhuo’s customer interface path is shorter than the multi-layer structure of “factory—trader—customer.” When customers raise needs for impurity reference standards, process route discussions, accelerated stability data for samples, or customized packaging, we can directly mobilize R&D and pilot resources to respond, rather than repeatedly relaying messages through intermediate links. We adhere to the positioning of “professional and rapid technical and production services.” Our goal is not to be the largest supplier, but to be the most worry-free and long-term reliable partner for customers in heterocyclic intermediates.

Welcome to visit our official website: https://www.shlzpharma.com/

On the product page, you can directly view the supply information for 3-amino-4-methyl-6-chloropyridazine (CAS 64068-00-4), or obtain batch COA, process discussions, sample arrangements, and ton-scale quotations through the contact information on the official website. Choosing Lizhuo means choosing not just a quotation, but a scalable supply path from gram scale to ton scale and from route to compliance.